Foretinib

Foretinib

Names
IUPAC name N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
CAS Number	849217-64-7 Y
ChEMBL	ChEMBL1908393
ChemSpider	24608641
Jmol 3D model	Interactive image
UNII	81FH7VK1C4
InChI InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
SMILES COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Properties
Chemical formula	C34H34F2N4O6
Molar mass	632.66 g·mol−1
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 no phase III trials are registered.

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).

See also

• c-Met inhibitors
• Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
• VEGFR inhibitor
• tyrosine-kinase inhibitor